Last reviewed · How we verify
intravitreal injection of triamcinolone acetonide
intravitreal injection of triamcinolone acetonide is a Small molecule drug developed by Retina Associates of Florida, P.A.. It is currently in Phase 2 development. Also known as: control arm.
At a glance
| Generic name | intravitreal injection of triamcinolone acetonide |
|---|---|
| Also known as | control arm |
| Sponsor | Retina Associates of Florida, P.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients (PHASE4)
- IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes (NA)
- Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization (PHASE2, PHASE3)
- Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study (PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Triamcinolone vs. Laser for Diabetic Macular Edema (NA)
- Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravitreal injection of triamcinolone acetonide CI brief — competitive landscape report
- intravitreal injection of triamcinolone acetonide updates RSS · CI watch RSS
- Retina Associates of Florida, P.A. portfolio CI
Frequently asked questions about intravitreal injection of triamcinolone acetonide
What is intravitreal injection of triamcinolone acetonide?
intravitreal injection of triamcinolone acetonide is a Small molecule drug developed by Retina Associates of Florida, P.A..
Who makes intravitreal injection of triamcinolone acetonide?
intravitreal injection of triamcinolone acetonide is developed by Retina Associates of Florida, P.A. (see full Retina Associates of Florida, P.A. pipeline at /company/retina-associates-of-florida-p-a).
Is intravitreal injection of triamcinolone acetonide also known as anything else?
intravitreal injection of triamcinolone acetonide is also known as control arm.
What development phase is intravitreal injection of triamcinolone acetonide in?
intravitreal injection of triamcinolone acetonide is in Phase 2.
Related
- Manufacturer: Retina Associates of Florida, P.A. — full pipeline
- Also known as: control arm
- Compare: intravitreal injection of triamcinolone acetonide vs similar drugs
- Pricing: intravitreal injection of triamcinolone acetonide cost, discount & access